Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-2-307-MAB in advanced cancer
NCT05159440Phase 1Active, not recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of TORL-2-307-MAB in solid tumor (advanced stage), gastric cancer (GC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by TORL BioTherapeutics. Primary endpoints: Incidence and severity of adverse events and serious adverse events up to 2 years, Maximum Tolerated Dose at 28 Days and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
TORL-2-307-MAB
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)pancreatic cancer (PC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05159440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159440.